Tags : HLH


Sobi’s Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis

Shots: The approval is based on P-II/III (NCT01818492) study results assessing Gamifant IV in patients with primary HLH, evaluating its safety, efficacy and tolerability The P-II/III study resulted in meeting 1EPs with meaningful and significant overall response and 70% achieved HSCT  Gamifant (emapalumab) IV is a mAb with its directed usage of over one hour […]Read More